Comparison
3 Methylglutaconic Aciduria Type 4 C1855126 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Methylglutaconic Aciduria Type 4 and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 4 C1855126
A metabolic disorder affecting the nervous system that typically begins in childhood. Patients may experience movement difficulties, muscle stiffness, and developmental challenges. Care involves supportive therapies and symptom management.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 4 C1855126
0-null
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 4 C1855126
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 4 C1855126
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 4 C1855126
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-4-C1855126 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 4 C1855126 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Movement and muscle tone | Movement difficulty and muscle stiffness may occur. | Not specifically described; physical features may occur. | Moderate |
| Development | Developmental challenges may accompany neurologic involvement. | Developmental delay is a described concern. | Low |
| Behavior | Behavioral features are not established in the supplied data. | Behavioral concerns may be present. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 4 C1855126 when
Childhood neurologic and metabolic presentation
Supplied description emphasizes nervous-system involvement beginning typically in childhood.
Moderate
Prominent movement difficulty or stiffness
These features are specifically mentioned for the metabolic condition.
Moderate
Need to distinguish an abnormal metabolite result
An abnormal organic-acid finding suggests evaluation, but is not itself this diagnosis.
High
Choose 17q11 2 Microduplication Syndrome C3495679 when
Suspected chromosomal copy-number condition
The syndrome is defined by duplication of a 17q11.2 segment.
High
Developmental delay with behavioral concerns
Both are described, although neither is specific.
Moderate
Congenital presentation needing early intervention
Supplied care focus is early intervention rather than metabolic management.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 4 C1855126 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Urine organic-acid analysis | May show abnormal 3-methylglutaconic acid; cutoff not supplied. | No characteristic organic-acid abnormality is established here. | An abnormal result is not a diagnosis and needs specialist confirmation. |
| Chromosomal microarray | Not the defining test in the supplied description. | May identify a 17q11.2 duplication. | Copy-number findings require laboratory and clinical correlation. |
| Neurologic examination | May document movement difficulty or stiffness. | May document developmental or behavioral concerns and physical features. | Examination supports referral but cannot distinguish these conditions alone. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 4 C1855126
- Outcome
- Potentially serious chronic neurologic course, but individual outcome is not established.
- Factors
- Severity, neurologic findings, and response to supportive care may matter.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Often described as moderate, with variable developmental and behavioral needs.
- Factors
- Duplication findings, developmental profile, and access to early intervention may matter.
Time frame: Long-term; exact onset and survival data are not supplied.
Clinician interpretation is required because source evidence is sparse.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Potentially prominent given severe neurologic description. Not specifically established beyond developmental concerns. Severity and course vary; exact outcomes are not supplied. |
| Developmental disability | Developmental challenges may occur. Developmental delay may occur. Shared concern with different proposed mechanisms. |
| Behavioral difficulty | Not established from supplied data. Behavioral concerns are described. Do not infer a specific psychiatric diagnosis. |
Patient education highlights
- HighDiagnosis requires confirmation
Names, symptoms, and abnormal tests do not by themselves prove either condition.
- HighCare is supportive
Described management is supportive therapy, symptom care, or early intervention; no dose is established here.
- MediumNeither is contagious
Both are described as noncommunicable, although inheritance details are not supplied.